Program
VCT220
A development code. Also written as “CX11”, “CX11 (VCT220)” and “VCT220 tablets”.
Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Hypertension, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Vincentage Pharma | 92 open or running | phase 3since Apr 10, 2025 | Aug 20, 2024 | Jul 1, 2027phase 2 · NCT07872436 |
| Corxel Pharmaceuticals | 32 open or running | phase 2since Jun 2, 2025 | Jun 2, 2025 | Mar 2027phase 1 · NCT07652047 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 20, 2024First study: phase 2 study in ObesityNew to Vincentage PharmaVincentage Pharma · NCT06569355 · 250 enrolled · China
- Apr 10, 2025Phase 3 study in ObesityVincentage Pharma · NCT06939296 · 840 enrolled · China
- Apr 14, 2025Phase 1 study in ObesityVincentage Pharma · NCT06938529 · 24 enrolled · China
- Jun 2, 2025Corxel Pharmaceuticals's first study: phase 2 study in ObesityNew to Corxel PharmaceuticalsCorxel Pharmaceuticals · NCT07011797 · 250 enrolled · United States
- Jun 24, 20252 phase 1 studies in ObesityVincentage Pharma · NCT07065058, NCT07056842
- Dec 22, 2025Phase 1 study in ObesityVincentage Pharma · NCT07347808 · 16 enrolled · China
- Jan 8, 2026Phase 1 study in ObesityVincentage Pharma · NCT07349381 · 32 enrolled · China
- Jan 9, 2026Phase 2 study in HypertensionVincentage Pharma · NCT07360275 · 160 enrolled · China
- Jan 13, 2026Phase 2 study in Diabetes Mellitus, Type 2Corxel Pharmaceuticals · NCT07340320 · 251 enrolled · United States, Poland
- Jun 11, 2026Phase 1 study in ObesityCorxel Pharmaceuticals · NCT07652047 · 90 planned · United States
- Sep 19, 2026Phase 2 study in Diabetes Mellitus, Type 2Vincentage Pharma · NCT07872436 · 120 planned · China
Ahead
- Mar 2027Primary completion: phase 1 study in ObesityCorxel Pharmaceuticals · NCT07652047
- Apr 8, 2027Primary completion: phase 2 study in Diabetes Mellitus, Type 2Corxel Pharmaceuticals · NCT07340320
- Jul 1, 2027Primary completion: phase 2 study in Diabetes Mellitus, Type 2Vincentage Pharma · NCT07872436
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 12 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07872436Diabetes Mellitus, Type 2 · China | 2 | Not yet recruiting | Vincentage Pharma | Jul 1, 2027 | 120 |
| NCT07652047Obesity · United States | 1 | Recruiting | Corxel Pharmaceuticals | Mar 2027 | 90 |
| NCT07340320Diabetes Mellitus, Type 2 · United States, Poland | 2 | Active, not recruiting | Corxel Pharmaceuticals | Apr 8, 2027 | 251 |
| NCT07360275Hypertension · China | 2 | Active, not recruiting | Vincentage Pharma | Oct 30, 2026 | 160 |
| NCT07349381Obesity · China | 1 | Completed | Vincentage Pharma | Jun 30, 2026 | 32 |
| NCT07347808Obesity · China | 1 | Completed | Vincentage Pharma | Jan 18, 2026 | 16 |
| NCT07056842Obesity · China | 1 | Completed | Vincentage Pharma | Aug 11, 2025 | 32 |
| NCT07065058Obesity · China | 1 | Completed | Vincentage Pharma | Jul 11, 2025 | 24 |
| NCT07011797Obesity · United States | 2 | Completed | Corxel Pharmaceuticals | Mar 23, 2026 | 250 |
| NCT06938529Obesity · China | 1 | Completed | Vincentage Pharma | Jul 15, 2025 | 24 |
| NCT06939296Obesity · China | 3 | Completed | Vincentage Pharma | Nov 25, 2025 | 840 |
| NCT06569355Obesity · China | 2 | Completed | Vincentage Pharma | Jul 13, 2024 | 250 |
How it is read
Names in the registry
- “CX11”, 4 entries
- “VCT220”, 4 entries
- “CX11 (VCT220)”, 1 entry
- “VCT220 tablets”, 1 entry
- “VCT220 Tablet”, 1 entry
Codes read as this program: CX11, VCT220.
Conditions, from the studies’ own filings
- Obesity, 9 studies
- Diabetes Mellitus, Type 2, 2 studies
- Hypertension, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.